Discovery of virus implicated in genetics of prostate cancer

NewsGuard 100/100 Score

The Open Access journal PLoS Pathogens has published an article detailing research that identifies a new retrovirus in the tissue of human prostate tumors.

The research was first announced at an American Society of Clinical Oncology Meeting, but only now is the full, peer-reviewed report available.

The paper, entitled "Identification of a Novel Gammaretrovirus in Prostate Tumors of Patients Homozygous for R462Q RNASEL Variant," reports that the researchers detected the new virus more frequently in men with mutations in both their copies of RNASEL than in those with at least one normal copy.

Scientists have long speculated about a connection between cancer and infectious diseases. The possible connection has been especially true in the case of prostate cancer because a variant on the viral-defense gene, RNASEL, has been implicated in 15% of prostate cancer cases. The newly discovered virus is closely related to virus associated with leukemia in mice.

"We have made a very fascinating discovery never before seen in humans that is very similar to one found in a mammal that causes cancer," said Dr. Eric Klein of the Cleveland Clinic. "But we have not proven this virus causes prostate cancer."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Amgen plows ahead with costly, highly toxic cancer dosing despite FDA challenge